[Skip to Content]
[Skip to Content Landing]
Views 224
Citations 0
Comment & Response
November 27, 2018

Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment—Reply

Author Affiliations
  • 1School of Medicine, University of Alabama at Birmingham
  • 2University Hospital Zurich, Zurich, Switzerland
  • 3University of California, San Diego, La Jolla
JAMA. 2018;320(20):2154. doi:10.1001/jama.2018.15946

In Reply As stated in the panel’s report,1 the relative absence of resistance-conferring mutations for InSTI drugs supports the recommendation to not test routinely for InSTI resistance before start of HIV treatment. A summary of existing data regarding the relative lack of transmission of InSTI resistance–conferring mutations was published this year.2